Reduced levels of the cell-cycle inhibitor p27(Kip1) in epithelial dysplasia and carcinoma of the oral cavity

American Journal of Pathology

Volumn 152, Issue 2, 1998, Pages 585-590

  Jordan, Richard C K ^a,b,e   Bradley, Grace ^a   Slingerland, Joyce ^c,d  

^a Department of Oral Pathology ^*  (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Cancer Biology Research Group   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR; KI 67 ANTIGEN; PROTEIN P27;

ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM DYSPLASIA; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUTH CARCINOMA; PRIORITY JOURNAL;

CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL CYCLE PROTEINS; CROSS-SECTIONAL STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENZYME INHIBITORS; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; MOUTH MUCOSA; MOUTH NEOPLASMS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEINS;

EID: 0031883583     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Cohen SM, Ellwein LB: Cell proliferation in carcinogenesis. Science 1990, 249:1007-1011
2. Williams AC, Browne SJ, Manning AM, Hague A, van der Stappen JW, Paraskeva C: Biological consequences of the genetic changes which occur during human colorectal carcinogenesis. Sem Cancer Biol 1993, 4:153-159
3. Coltrera MD, Zarbo RJ, Sakr WA, Gown AM: Markers for dysplasia of the upper aerodigestive tract: suprabasal expression of PCNA, p53, and CK19 in alcohol-fixed, embedded tissue. Am J Pathol 1992, 141:817-825
4. Girod SC, Pape HD, Krueger GR: p53 and PCNA expression in carcinogenesis of the oropharyngeal mucosa. Oral Oncol Eur J Cancer 1994, 30(B):419-423
5. Huang WY, Coltrera M, Schubert M, Morton T, Truelove E: Histopathologic evaluation of proliferating cell nuclear antigen (PC10) in oral epithelial hyperplasias and premalignant lesions. Oral Surg Oral Med Oral Pathol 1994, 78:748-754
6. Girod SC, Krueger G, Pape HD: p53 and Ki 67 expression in preneoplastic and neoplastic lesions of the oral mucosa. Int J Oral Maxillofacial Surg 1993, 22:285-288
7. Kannan S, Chandran GJ, Pillai KR, Mathew B, Sujathan K, Nalinakumary KR, Nair MK: Expression of p53 in leukoplakia and squamous cell carcinoma of the oral mucosa: correlation with expression of Ki-67. J Clin Pathol Mol Pathol 1996, 49:170-175
8. Warnakulasuriya KA, Johnson NW: Association of overexpression of p53 oncoprotein with the state of cell proliferation in oral carcinoma. J Oral Pathol Med 1994, 23:246-250
9. Mukhopadhyay D, Chatterjee R, Chakraborty RN: Cytokinetic studies of oral cancer cells using bromodeoxyuridine labelling in relation to factors influencing prognosis. Eur J Cancer 1995, 31(B):32-36
10. Tsuji T, Shrestha P, Yamada K, Takagi H, Shinozaki F, Sasaki K, Maeda K, Mori M: Proliferating cell nuclear antigen in malignant and pre-malignant lesions of epithelial origin in the oral cavity and the skin: an immunohistochemical study. Virchows Arch A Pathol Anat Histopathol 1992, 420:377-383
11. Shin DM, Voravud N, Ro JY, Lee JS, Hong WK, Hittelman WN: Sequential increases in proliferating cell nuclear antigen expression in head and neck tumorigenesis: a potential biomarker. J Natl Cancer Inst 1993, 85:971-978
12. Zoeller J, Flentje M, Sinn P, Born IA: Evaluation of AgNOR and Ki-67 antigen as cell kinetic parameters in oral dysplasias and carcinomas. Anal Cell Pathol. 1994, 7:77-88
13. Sherr CJ: G1 phase progression: cycling on cue. Cell 1994, 79:551-555
14. Morgan DO: Principles of CDK regulation. Nature 1995, 374:131-134
15. Solomon MJ: Activation of the various cyclin/cdc2 protein kinases. Curr Opin Cell Biol 1993, 5:180-186
16. Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI: A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci USA 1994, 91:5291-5295
17. Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D, Slingerland J: G1 control in mammalian cells. J Cell Sci Suppl 1994, 18:69-73
18. Murray AW: Creative blocks: cell-cycle checkpoints and feedback controls. Nature 1992, 359:599-604
19. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992, 71:543-546
20. Pines J: Cyclins, CDKs, and cancer. Semin Cancer Biol 1995, 6:63-72
21. Aprelikova O, Xiong Y, Liu ET: Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. J Biol Chem 1995, 270:18195-18197
22. Hall M, Bates S, Peters G: Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 1995, 11:1581-1588
23. Lee MH, Reynisdottir I, Massague J: Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev 1995, 9:639-649
24. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825
25. Gu Y, Turck CW, Morgan DO: Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 1993, 366:707-710
26. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper, JW, Elledge SJ: p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995, 9:650-662
27. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J: Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994, 78:59-66
28. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A: p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev 1994, 8:9-22
29. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med 1997, 3:222-225
30. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin, P, Draetta G, Pagano M, Loda M: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res 1997, 57:1259-1263
31. Hori M, Kamijo R, Takeda K, Nagumo M: Downregulation of c-myc expression by tumor necrosis factor-α in combination with transforming growth factor-β or interferon-γ with concomitant inhibition of proliferation in human cell lines. J Interferon Res 1994, 14:49-55
32. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 1993, 366:701-704
33. Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI: A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol Cell Biol 1994, 14:3683-3694
34. kip1protein: prognostic implications in primary breast cancer. Nature Med 1997, 3:227-230
35. Lloyd RV, Jin L, Qian X, Kulig E: Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol 1997, 150:401-407
36. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup, JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 1997, 3:231-234
37. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T: p27 expression and gastric carcinoma. Nature Med 1997, 3:593
38. Kotelnikov VM, Coon JS, Mundle S, Kelanie S, LaFollette S, Taylor S, Caldarelli DD, Preisler HD: Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis. Clin Cancer Res 1997, 3:95-101
39. Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A: Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res 1995, 55:975-978
40. Kaur J, Srivastava A, Ralhan R: Overexpression of p53 protein in betel-and tobacco-related human oral dysplasia and squamous-cell carcinoma in India. Int J Cancer. 1994, 58:340-345
41. Nishioka H, Hiasa Y, Hayashi I, Kitahori Y, Konishi N, Sugimura M: Immunohistochemical detection of p53 oncoprotein in human oral squamous cell carcinomas and leukoplakias: comparison with proliferating cell nuclear antigen staining and correlation with clinicopathological findings. Oncology 1993, 50:426-429
42. Shin DM, Kim J, Ro JY, Hittelman J, Roth JA, Hong WK, Hittelman WN: Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994, 54:321-326
43. MacDonald DG, Saka SM: Structural indicators of the high risk lesion. Risk Markers for Oral Diseases. Edited by Johnson NW. Cambridge, UK, Cambridge University Press, 1991, pp 165-87
44. Norton AJ, Jordan S, Yeomans P: Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 1994, 173:371-379
45. Key G, Becker MH, Baron B, Duchrow M, Schluter C, Flad HD, Gerdes J: New Ki-67-equivalent murine monoclonal antibodies (MIB 1-3) generated against bacterially expressed parts of the Ki-67 cDNA containing three 62 base pair repetitive elements encoding for the Ki-67 epitope. Lab Invest 1993, 68:629-636
46. Girard F, Strausfeld U, Fernandez A, Lamb NJ: Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 1991, 67:1169-1179
47. Hirama T, Koeffler HP: Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995, 86:841-854
48. Yeudall WA, Crawford RY, Ensley JF, Robbins KC: MTS1/CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis 1994, 15:2683-2686
49. Matsuda H, Konishi N, Hiasa Y, Hayashi I, Tsuzuki T, Tao M, Kitahori Y, Yoshioka N, Kirita T, Sugimura M: Alterations of p16/CDKN2, p53 and ras genes in oral squamous cell carcinomas and premalignant lesions. J Oral Pathol Med 1996, 25:232-238
50. Game SM, Stone A, Matthews JB, Scully C, Prime SS: Differentiation of malignant oral rat keratinocytes reflects changes in EGF and TGF-β receptor expression but not growth factor dependence. Carcinogenesis. 1991, 12:409-416
51. Paterson IC, Patel V, Sandy JR, Prime SS, Yeudall WA: Effects of transforming growth factor β-1 on growth-regulatory genes in tumour-derived human oral keratinocytes. Br J Cancer 1995, 72:922-927
52. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY: Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996, 85:707-720
53. Califano J, van der Riet P, Westra W, Nawroz H, dayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D: Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996, 56:2488-2492
54. Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery, K, Mathew S, Krauter K, Sheinfeld J, Massague J, Cordon-Cardo C: p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995, 55:1211-1214
55. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994, 78:67-74
56. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A: Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996, 85:721-732
57. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996, 85:733-744
58. kip1 in lymphoid tissue. Am J Pathol 1997, 151:151-160
59. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269:682-685